Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Approvals Action
Two new neuro drugs

Posted 28 September 2020 

The TGA has approved two new therapies that treat neurological conditions - Emerge Health's Epidyolex and Maxx Pharma's Ongentys - along with the first generic version of Janssen's Ribomustin sponsored by Sydney-based Luminaire.

Epidyolex is a cannabis-based prescription medicine indicated as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome for patients two years and older while Ongentys provides a new option for Parkinson's disease.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
Aust Covid Vaccine Tracker
UPDATES: UNICEF stockpiling one billion syringes
Approvals Action
Shakeup for insulin
New biosim plus hypertension and herpes generics
Top of the Hill
Avoiding the Emperor's mistake
Not everyone is convinced about industry's budget win